Telemedicine is a growing resources for Houstonians, but here's what you need to know about tapping into digital health care. Ian Hooton/Getty Images

When health issues crop up, people often have to decide where best to seek medical attention, with urgent care and the emergency room being potential destinations. But for more and more Houston residents, their smartphone is now the preferred way to see and talk to a doctor.

Telemedicine visits, also known as virtual care, typically last less than 20 minutes, often cost less than $50 and enable people to connect 24/7 with a health care provider via a smartphone, tablet or personal computer to help diagnose and treat certain medical conditions. While nearly 40 percent of Americans said they are interested in using telemedicine in the future to access care a separate J.D. Power survey found nationwide telehealth adoption is currently as low as 10 percent.

Closing this gap by expanding the use of virtual care may prove beneficial, as this technology can provide consumers improved convenience and lower costs. In fact, 68 percent of patients rated their telemedicine visit a "nine" or "10" on a 10-point satisfaction scale; 74 percent had their care concern resolved during the first visit; and net savings per virtual visit exceeded $120.

To help people take advantage of this emerging technology, here are four tips to consider:

Identify Available Resources
Among people who had not used telemedicine, the J.D. Power survey found that 37 percent said they did not know if they had access to this technology. To find telemedicine resources that may be available to you, check with your hospital or care provider group, health insurance plan or employer. In fact, nearly nine out of 10 employers are offering telemedicine to their employees, while 76 percent of U.S. hospitals already connect patients and care providers using video or other technology. For Medicare beneficiaries, some Medicare Advantage plans are offering coverage for telemedicine and resources to access virtual care, in some cases at no out-of-pocket cost.

For Houston residents, most people enrolled in UnitedHealthcare employer-sponsored plans have coverage for virtual physician visits, giving plan participants secure, online access to a physician via mobile phone, tablet or computer 24 hours a day. Several Houston-area hospitals and provider groups have also introduced virtual care resources, and changes in state regulations in 2017 helped spur additional national telemedicine companies to start serving the market.

Understand Appropriate Uses
While telemedicine may have the potential to help treat other health issues, the technology is most widely used to address minor and nonemergency medical conditions, including allergies, flu, pinkeye, and rashes. Telemedicine is also emerging as a helpful resource for behavioral health services, making it more convenient for people to access this type of care. If needed, doctors can prescribe medications and send prescriptions to local pharmacies for pickup. While people who experience a significant or serious medical issue should go to the emergency room (ER), it is important to recognize that about 25 percent of ER visits typically involve conditions that could appropriately be addressed with a virtual visit.

Keep Your Primary Care Physician
Telemedicine may be ideal for treating minor and nonemergency medical issues, but it is important for people to maintain a relationship with a primary care physician for wellness checkups, diagnostics, management of long-term conditions and some urgent and non-urgent treatments. As telemedicine programs evolve, people may have the option to use virtual visits to access primary care and maintain an on-going relationship with their preferred doctor.

Other Connected Devices
Consumers can consider other connected devices to help access care and potentially improve their health, ranging from smartwatches and activity trackers to continuous blood glucose monitors and connected asthma inhalers. These connected devices – and others like them – may provide important real-time information and offer people actionable feedback about their behavior patterns, while helping make it possible for care providers to counsel patients to more effectively follow recommended treatments.

Making telemedicine more widely available – and used – may be especially important for people with chronic conditions and the 20 percent of the U.S. population that lives in rural areas where access to health care, particularly specialty care, is often lacking. By considering these tips, people may make the most of telemedicine resources as part of their journey toward managing their health.

------

Dave Milich is the CEO of UnitedHealthcare of Texas.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Meta to bring $115 million AI data center training initiative to Houston

ai workforce

Meta and Associated Builders and Contractors have entered into a partnership to invest $115 million in training programs for the construction of AI data centers, with a portion of the project launching in Houston.

The companies announced June 8 that they would open America’s Workforce Academies at ABC chapter training centers in Houston; Indianapolis; Baton Rouge, Louisiana; and Columbus, Ohio.

The academies will offer career readiness and safety training, plus five weeks of hands-on education. Participants who complete the program will be granted a job offer from contractors working on Meta projects.

“The AI revolution is bringing change but also historic opportunities,” Dina Powell McCormick, Meta president and vice-chairman, said in a news release. “Skilled workers electrified rural America one pole at a time. They manned the factories that built the arsenal that won World War II. Now a new generation will pour the foundations and lay the fiber that secures American strength in this new age.”

Overall, the Meta and ABC aim for the academies to build a more sustainable pipeline of skilled construction workers and ensure safety and job readiness for the surging number of data center projects underway.

“This new program is an innovative talent solution that is a critical part of addressing the construction industry’s ongoing workforce shortage and creates an accelerated, new-entrant strategy for job seekers ... The sustained demand for data center construction technicians means the industry needs an all-of-the-above approach to address this shortage and grow the construction talent pool,” Michael Bellaman, ABC president and CEO, added in the release.

In Texas, Meta, the parent company of Facebook and Instagram, has launched or broken ground on data centers in El Paso, Fort Worth and Temple. The company announced in March that it planned to grow its El Paso Data center by 1 gigawatt, representing more than a $10 billion investment.

Apart from Meta, Texas has attracted data center development to power other giants like Google and Amazon in recent years. In turn, Texas has been predicted to become the biggest data center market. Commercial real estate services provider JLL reported this spring that the state could topple Northern Virginia as the world’s largest data-center market by 2030. Similarly, CBRE predicted that Houston's data center capacity could double by 2028. Read more here.

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”